Sequenom Misrepresented Medical Advancements: Suit

Law360, New York (October 29, 2009, 5:43 PM EDT) -- Medical testing developer Xenomics Inc. is asking a New York state court to grant as much as $300 million in damages from a company it says breached a patent licensing agreement by misrepresenting medical advancements for Down syndrome testing.

In a suit lodged Wednesday in the New York State Supreme Court, Xenomics claims it was fraudulently induced to forge an agreement in October 2008 to sell biotech company Sequenom Inc. exclusive licensing rights for several patents related to tests designed to detect Down Syndrome in fetuses....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.